Momenta Phama (MNTA) Misses Q4 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. NDAQ
9. TSCO
10. BE

Go back to Momenta Phama (MNTA) Misses Q4 EPS by 5c

Momenta (MNTA) Buy Rating Maintained at UBS (Earlier)

February 18, 2015 3:33 PM EST

UBS earlier maintained a Buy rating on Momenta Pharmaceuticals (NASDAQ: MNTA) and lowered its price target to $15.00 (from $18.00). The change follows Q4 results and comments during the call. Analyst Marc Goodman said his thesis hasn't changed.

"The FDA has said that there is nothing outstanding for the Copaxone application and mgt believes the... More